Haiying Cheng1, Yiyu Zou2, Chirag D Shah3, Ni Fan2, Tushar D Bhagat2, Rasim Gucalp2, Mimi Kim4, Amit Verma2, Bilal Piperdi5, Simon D Spivack3, Balazs Halmos2, Roman Perez-Soler6. 1. Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY10461, USA. Electronic address: hcheng@montefiore.org. 2. Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY10461, USA. 3. Division of Pulmonary Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY10461, USA. 4. Department of Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, NY10461, USA. 5. Merck Research Laboratories, Rahway, NJ07065, USA. 6. Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY10461, USA. Electronic address: rperezso@montefiore.org.
Abstract
BACKGROUND: Aerosolized Azacitidine has been shown to inhibit orthotopic lung cancer growth and induce re-expression of methylated tumor suppressor genes in murine models. We hypothesized that inhaled Azacitidine is safe and effective in reversing epigenetic changes in the bronchial epithelium secondary to chronic smoking. PATIENTS AND METHODS: We report the first in human study of inhaled Azacitidine. Azacitidine in aqueous solution was used to generate an aerosol suspension of 0.25-5 μm particle size. Main inclusion criteria: Stage IV or recurrent NSCLC with predominantly lung involvement, ≥1 prior systemic therapy, ECOG PS 0-1, and adequate pulmonary function. Patients received inhaled Azacitidine daily on days 1-5 and 15-19 of 28-day cycles, at 3 escalating doses (15, 30 and 45 mg/m2 daily). The primary objective was to determine the feasibility and tolerability of this new therapeutic modality. The key secondary objectives included pharmacokinetics, methylation profiles and efficacy. RESULTS: From 3/2015 to 2/2018, eight patients received a median number of 2 (IQR = 1) cycles of inhaled Azacitidine. No clinically significant adverse events were observed, except one patient treated at the highest dose developed an asymptomatic grade 2 decreased DLCO which resolved spontaneously. One patient receiving 12 cycles of therapy had an objective and durable partial response, and two patients had stable disease. Plasma Azacitidine was only briefly detectable in patients treated at the higher doses. Moreover, in 2 of 3 participants who agreed and underwent pre- and post-treatment bronchoscopy, the global DNA methylation in the bronchial epithelium decreased by 24 % and 79 % post-therapy, respectively. The interval between last inhaled treatment and bronchoscopy was 3 days. CONCLUSIONS: Inhaled Azacitidine resulted in negligible plasma levels compared to the previously reported subcutaneous administration and was well-tolerated. The results justify the continued development of inhaled Azacitidine at non-cytotoxic doses for patients with lung-confined malignant and/or premalignant lesions.
BACKGROUND: Aerosolized Azacitidine has been shown to inhibit orthotopic lung cancer growth and induce re-expression of methylated tumor suppressor genes in murine models. We hypothesized that inhaled Azacitidine is safe and effective in reversing epigenetic changes in the bronchial epithelium secondary to chronic smoking. PATIENTS AND METHODS: We report the first in human study of inhaled Azacitidine. Azacitidine in aqueous solution was used to generate an aerosol suspension of 0.25-5 μm particle size. Main inclusion criteria: Stage IV or recurrent NSCLC with predominantly lung involvement, ≥1 prior systemic therapy, ECOG PS 0-1, and adequate pulmonary function. Patients received inhaled Azacitidine daily on days 1-5 and 15-19 of 28-day cycles, at 3 escalating doses (15, 30 and 45 mg/m2 daily). The primary objective was to determine the feasibility and tolerability of this new therapeutic modality. The key secondary objectives included pharmacokinetics, methylation profiles and efficacy. RESULTS: From 3/2015 to 2/2018, eight patients received a median number of 2 (IQR = 1) cycles of inhaled Azacitidine. No clinically significant adverse events were observed, except one patient treated at the highest dose developed an asymptomatic grade 2 decreased DLCO which resolved spontaneously. One patient receiving 12 cycles of therapy had an objective and durable partial response, and two patients had stable disease. Plasma Azacitidine was only briefly detectable in patients treated at the higher doses. Moreover, in 2 of 3 participants who agreed and underwent pre- and post-treatment bronchoscopy, the global DNA methylation in the bronchial epithelium decreased by 24 % and 79 % post-therapy, respectively. The interval between last inhaled treatment and bronchoscopy was 3 days. CONCLUSIONS: Inhaled Azacitidine resulted in negligible plasma levels compared to the previously reported subcutaneous administration and was well-tolerated. The results justify the continued development of inhaled Azacitidine at non-cytotoxic doses for patients with lung-confined malignant and/or premalignant lesions.
Authors: Carmen S Tellez; Daniel E Juri; Kieu Do; Maria A Picchi; Teresa Wang; Gang Liu; Avrum Spira; Steven A Belinsky Journal: Cancer Res Date: 2016-06-14 Impact factor: 12.701
Authors: Benjamin P Levy; Giuseppe Giaccone; Benjamin Besse; Enriqueta Felip; Marina Chiara Garassino; Manuel Domine Gomez; Pilar Garrido; Bilal Piperdi; Santiago Ponce-Aix; Daniel Menezes; Kyle J MacBeth; Alberto Risueño; Ruta Slepetis; Xiaoling Wu; Abderrahim Fandi; Luis Paz-Ares Journal: Eur J Cancer Date: 2019-01-14 Impact factor: 9.162
Authors: Theresa Ryan Stueve; Wen-Qing Li; Jianxin Shi; Crystal N Marconett; Tongwu Zhang; Chenchen Yang; Daniel Mullen; Chunli Yan; William Wheeler; Xing Hua; Beiyun Zhou; Zea Borok; Neil E Caporaso; Angela C Pesatori; Jubao Duan; Ite A Laird-Offringa; Maria Teresa Landi Journal: Hum Mol Genet Date: 2017-08-01 Impact factor: 6.150
Authors: Philip J Kuehl; Carmen S Tellez; Marcie J Grimes; Thomas H March; Mathewos Tessema; David A Revelli; Larry M Mallis; Wendy W Dye; Tyler Sniegowski; Aaron Badenoch; Michael Burke; Devon Dubose; David T Vodak; Maria A Picchi; Steven A Belinsky Journal: Br J Cancer Date: 2020-02-27 Impact factor: 9.075
Authors: Kimberly B Shepard; David T Vodak; Philip J Kuehl; David Revelli; Yue Zhou; Amanda M Pluntze; Molly S Adam; Julia C Oddo; Lauren Switala; Jonathan L Cape; John M Baumann; Michael Banks Journal: AAPS PharmSciTech Date: 2021-08-31 Impact factor: 3.246